A monoclonal antibody that targets placental growth factor (PIGF) has been taken to the next stage of clinical development with the start of a Phase 1b/2 study in patients with glioblastoma multiforme, the most aggressive type of brain cancer. ---Subscribe to MedNous to access this article--- Company News
